An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Multiple cell and tissue atlas projects are underway around the globe. These efforts aim to produce community resources and foster an understanding of health and disease. Key needs for these atlas-building efforts include the following:
A suite of reference Standards for multiple molecular modalities that can be adopted easily by the research community to improve quality assurance/quality control and to ensure consistent, precise, and accurate measures over time
Appropriate Healthy Reference Tissue benchmarks as comparators for disease
The National Institute of Diabetes and Digestive and Kidney Diseases is planning a public workshop to discuss the challenges and best practices for obtaining and using healthy reference tissue as a benchmark for disease and for assessing the technical variability of imaging and -omic assays. This workshop also will identify state-of-the-art, fit-for-purpose standards for these assays and stimulate discussion of the next generation of standards. The workshop aims to address these issues through the lens of kidney precision medicine while surfacing lessons learned from other fields and sharing solutions that could enhance all atlas-building efforts broadly.
Organizing Committee
Carolyn Compton, M.D., Ph.D. (Arizona State University)
Petter Bjornstad, M.D. (Children’s Hospital Colorado)
Jeff Spraggins, Ph.D. (Vanderbilt University)
Christina M. Jones, Ph.D. (NIST)
Ben Neely, Ph.D. (NIST)
Tara Hiltke, Ph.D. (NIH/NCI)
Jasmin Bavarva, Ph.D. (NIH/NCI)
Tony Dickherber, Ph.D. (NIH/NCI)
Chris Ketchum, Ph.D. (NIH/NIDDK)
Danny Gossett, Ph.D. (NIH/NIDDK)
Eric Brunskill, Ph.D. (NIH/NIDDK)
Welcome
Robert Star, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Key Needs of Multiple National Institutes of Health (NIH) Atlas Efforts
To develop a suite of reference standards for multiple molecular modalities that can be adopted easily by the research community to improve quality assurance/quality control (QA/QC) and ensure consistent, precise, and accurate measures over time
To develop appropriate “healthy reference tissue” benchmarks as comparators for disease
Key Question for Workshop Participants
What healthy reference tissue(s) and/or standard(s) should I use when I run an experiment in my laboratory next week?
10:10 a.m. – 10:50 a.m.
Session One: Lessons Learned from Atlas Programs
10:10 a.m. – 10:30 a.m.
“Lessons Learned from Atlas Programs”
Carolyn Compton, M.D., Ph.D., Arizona State University
10:30 a.m. – 10:50 a.m.
“Lessons Learned from HuBMAP and nPOD Programs”
Mark Atkinson, Ph.D., University of Florida
Key Questions for Speakers
What do we know now about pre-analytics, QA/QC, and the inclusion of standards?
What are the challenges and current best practices for minimizing batch effects and technical variability to understand biological variability?
How do you prepare for different end user needs?
What potential sources of variability did you worry about most?
10:55 a.m. – 12:25 p.m.
Session Two: Understanding the Dual Role of “Healthy Tissues” as Standards and “Normal” Reference Tissue
10:55 a.m. – 11:10 a.m.
Stephen Hewitt, M.D., Ph.D., Center for Cancer Research, NCI
What are the current best practices for obtaining “healthy reference tissue”?
What quantitative metrics should be used to assess tissue quality?
How “normal” is adjacent “normal tissue”?
What are the limits of “no significant pathologic changes”?
What are the pitfalls of subtraction analysis?
What potential sources of variability do you worry about most?
12:25 p.m. – 12:45 p.m.
Break
12:45 p.m. – 2:15 p.m.
Session Three: Developing Assay-specific Community Standards: Current State-of-the-art Standards: Lessons
from the Bench
12:45 p.m. – 1:00 p.m.
Stephen Castellino (Xenovista LLC/GlaxoSmithKline)—Spatial Modalities
1:00 p.m. – 1:15 p.m.
Amanda Paulovich, M.D., Ph.D., Fred Hutchinson Cancer Research Center—Mass Spectrometry/Proteomics
1:15 p.m. – 1:30 p.m.
Charles Wang M.D., Ph.D., Loma Linda University—RNA/Molecular Assays
1:30 p.m. – 1:45 p.m.
Clay Davis, M.D.C.M., National Institute of Standards and Technology (NIST)—Metabolomics and Lipidomics
1:45 p.m. – 2:00 p.m.
Michael Rauchman, M.D., Washington University School of Medicine in St. Louis—Epigenetics
2:00 p.m. – 2:15 p.m.
Marc Salit, Ph.D., The MITRE Corporation—Genomics
Key Questions for Speakers
What standards have and have not worked?
What quantitative metrics should be used to assess standard quality?
What is the relative value of using reference tissue compared with fit-for-purpose standards? Does a role for both exist?
What potential sources of variability do you worry about most?
2:15 p.m. – 2:45 p.m.
Session Four: Lighting Talks: Late-breaking Innovative Ideas. Moving the Field Forward and Developing
Next Generation Fit-for-purpose Standards
2:15 p.m. – 2:20 p.m.
Improving spatial N-glycomics for human kidney using reference tissue and robust quality
control Chris Anderton, Ph.D., PNNL
2:20 p.m. – 2:25 p.m.
Nephrectomy Tissue as a Source for High Quality Reference Tissue Markus Bitzer, M.D.,
University of Michigan
2:25 p.m. – 2:30 p.m.
Long-Term Metabolomics Reference Material Goncalo Gouveia, Ph.D., University of Georgia
2:30 p.m. – 2:35 p.m.
Quality Control Metrics for Epigenetic Interrogation Technologies Michael Eadon, M.D.
Indiana University
2:35 p.m. – 2:40 p.m.
Aalim Weljie, Ph.D., University of Pennsylvania
2:40 p.m. – 2:45 p.m.
A Common Sample for Cross Platform, Multimodal Quality Control Standards of Spatial
Resolution Melissa Farrow, Ph.D. Vanderbilt University
Key Questions for Speakers
What are the gaps?
Where are the opportunities?
What are the new technologies that need to be improved or developed?
What emerging technologies will require new types of standards?
2:50 p.m. – 3:50 p.m.
Session Five: Breakout Discussions
With a background from prior sessions, discuss the current best practices and future needs. Where is technology development needed?
Key Question for Workshop Participants
What healthy reference tissue and/or standard should I use when I run an experiment in my laboratory next week?
Key Questions to Be Answered by Each Breakout Group
What are the current best practices?
What are the limitations to current best practices (pro and cons)?
What improvements or new developments need to be made? What can be attained or achieved in one year? Five years?
What community-wide experiments are needed to validate new technologies and standards?
What potential sources of variability do you worry about most?
Breakout Group Discussions
Discussion Leader(s)
Group 1. Pre-analytics
Carolyn Compton
Group 2. Healthy Reference Tissues
Petter Bjornstad
Group 3. Transcriptomics
Sanjay Jain/Charles Wang
Group 4. Proteomics
Jeff Spraggins /Ben Neely
Group 5. Metabolomics and Lipidomics
Chris Anderton/Tony Dickherber
Group 6. Epigenomics
Michael Rauchman/Mike Eadon
3:50 p.m. – 4:00 p.m.
Break
4:00 p.m. – 5:00 p.m.
Session Six: Breakout Reports (10 minutes each)
Breakout Group Discussions
Discussion Leader(s)
Group 1. Pre-analytics
Carolyn Compton
Group 2. Healthy Reference Tissues
Petter Bjornstad
Group 3. Transcriptomics
Sanjay Jain/Charles Wang
Group 4. Proteomics
Jeff Spraggins /Ben Neely
Group 5. Metabolomics and Lipidomics
Chris Anderton/Tony Dickherber
Group 6. Epigenomics
Michael Rauchman/Mike Eadon
5:00 p.m. – 5:10 p.m.
Closing Remarks and Adjournment
Event Logistics
Registration
Registration Closed
Registration ended
Location
Webinar
The web link needed to join this webinar will be distributed via email prior to the date of the event.
Contacts
Program Contact Daniel Gossett, Ph. D.
NIDDK
T: 301-594-7723
